This interplay between CSF orexin-A concentrations and the wide symptomatology presented by patients affected by AD principally considers the effect of the increase in nighttime wakefulness, reduction of REM sleep, and loss of the sleep-wake cycle, which has been well-documented in AD [3–4]. This evidence concerns the gene HCRT and Alzheimer disease.